Sign in
Taking people in South KoreaPhase 3

Weekly eloralintide for people with obesity or overweight but no diabetes

Tests weekly eloralintide in people with obesity or overweight, without diabetes.

Key facts

Who runs it
Eli Lilly and Company
Where
Namdong-gu, Seogu, Seongnam, Seoul, and Yangsan, South KoreaSee the 5 sitesAlso in 14 other countries, 152 sites
Trial code
Registry title
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Status
Recruiting
Phase
Phase 3
People taking part
1,980 people, planned
Started
6 Feb 2026
Expected to end
Jul 2030
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eloralintide
  • Placebo
Record updated
22 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity, or with overweight plus a weight-related health condition, who do not have diabetes.

Age
18 years or older
Sex
All sexes can join.
Disease stage
BMI of 30 kg/m2 or more, or BMI of 27 kg/m2 or more with high blood pressure, dyslipidemia, obstructive sleep apnea or heart disease. No type 1 or type 2 diabetes.
Earlier treatment
At least one self-reported unsuccessful diet effort to lose weight. No weight-loss medicines or remedies in the last 90 days. No past or planned weight-loss surgery, endoscopic procedure or device therapy, with some exceptions.

Main reasons for not taking part

  • Type 1 or type 2 diabetes
  • Weight change of 5% or more in the 90 days before screening
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospital stay for heart failure in the last 90 days
  • Class IV congestive heart failure
  • Prior or planned surgery, endoscopic procedure or device therapy for obesity, with some exceptions

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Have Body Mass Index (BMI) at screening of the following:; 30 kilogram per square meter (kg/m2) OR; 27 kg/m2 with at least one of the following weight-related health conditions at screening:; high blood pressure; dyslipidemia; obstructive sleep apnea, or; heart disease
  • Have a stable body weight (<5% body weight change) for 90 days prior to screening
  • Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes or type 2 diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where in South Korea

Also in 14 other countries, 152 sites

  • Gachon University Gil Medical CenterNamdong-gu, South KoreaContact: Kyoung-Kon Kim (principal investigator)Taking people
  • Konyang University HospitalSeogu, South KoreaContact: Jee Hyun Kang (principal investigator)Taking people
  • Seoul National University Bundang HospitalSeongnam, South KoreaContact: Kiheon Lee (principal investigator)Taking people
  • Seoul National University HospitalSeoul, South KoreaContact: Minseon Park (principal investigator)Taking people
  • Pusan National University Yangsan HospitalYangsan, South KoreaContact: Sang Yeoup Lee (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.

Read full original descriptionShow less

Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

The 5 groups in the trial

  • Eloralintide Dose 1Treatment being tested

    Participants will receive eloralintide subcutaneously (SC)

    Treatment: Eloralintide

  • Eloralintide Dose 2Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Eloralintide Dose 3Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Eloralintide Dose 4Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
Plain-language title
Weekly eloralintide for people with obesity or overweight but no diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
22 September 2026